ST Shuangcheng (002693.SZ): The approval of incretin peptide injection by the Australian Therapeutic Goods Administration (TGA) has been obtained.

Zhtng Cijng APP news, *ST Shung Chng (002693.SZ) has announced that the company has recently received market approval for the injection of etilefrine peptide from the Therapeutic Goods Administration (TGA) of Australia. Approved indications: suitable for patients undergoing non-emergency percutaneous coronary intervention and coronary artery stent implantation; suitable for the treatment of unstable angina or non-Q wave myocardial infarction patients.